The Serotonin System: History, Neuropharmacology, and Pathology provides an up-to-date accounting on the physiology and pathophysiology of serotonin and the role it plays in behavioral functions. In addition, the book explores the potential roles of 5-HT1 in neurodevelopmental disorders and summarizes the history of the discovery and development of serotonergic drugs for the treatment of neuropsychiatric disorders. This concise, yet thorough, volume is the perfect introduction to this critical neurotransmitter. It is ideal for students and researchers new to the study of behavior, neuropsychiatry or neuropharmacology, but is also a great resource for established investigators who want a greater perspective on serotonin.
- Examines the role of serotonin in physiological functions and neuropsychiatric disorders
- Provides in-depth knowledge on all aspects of the serotonin system
- Explores serotonergic receptors as targets for both current and new therapeutic compounds
1. Discovery of Serotonin and its Rise to Prominence 2. Neuronal and Peripheral Routes of Serotonergic Metabolism 3. The Serendipitous Path to Clinical Utility 4. Roles in Neurodevelopment and Stress 5. Defining the Anatomical Pathways and Their Electrophysiology 6. Serotonergic Biomarkers of Intellectual Impairment and Autism Spectrum Disorders 7. First Generation Drugs and Tools, Agonists, Antagonists, Synthesis Inhibitors, Neurotoxins, Releasing Agents, Monoamine Oxidase Inhibitors 8. Rodent and Human Anatomy Pathways, Structural and Functional Imaging 9. Metabolism 10. The Receptor Revolution: The 5-HT1 Subgroups, 5-HT2 Other Subtypes 11. What Did 5-HT3 Receptor Antagonists Teach Us about How Not to Do Drug Discovery? 12. Affective Behavior/Depression Anxiety 13. Sleep 14. Sexual Behavior 15. Cognitive Flexibility, Impulsivity, and Obsessive Compulsive Disorders 16. Anxiety, Aggression, and Endocrine Control, Neurogenesis, Stroke, and Alzheimer's Disease 17. Food Intake 18. Nociceptive Processing 19. Developmental Aspects Including Autism, Mental Retardation and Schizophrenia 20. Gene Environment Interactions 21. Overall Clinical Contribution and Successes and Failures 22. Future Outlook
Dr. Mark David Tricklebank, BSc MSc PhD DSc FBphS, earned his PhD from the University of Manchester, and after completing postdoctoral training at the Institute of Neurology, he joined the pharmaceutical company Merrell Dow in Strasbourg, where he was instrumental in the identification of the functional relevance of the newly identified 5-HT1A recognition site. He then moved to Merck at Terlings Park, where he worked with Susan Iversen to identify the behavioral effects of the NMDA receptor antagonist MK-801 and showed them to be identical to those of phencyclidine and ketamine. After then serving as head of the Mental Health Unit at Sandoz Pharma in Basel, he was appointed director of In Vivo Pharmacology at the Lilly Research Centre, Windlesham, where he conceived and founded the Lilly Centre for Cognitive Neuroscience, one of the first industrial-academic partnerships in the United Kingdom. After a storied career of several decades in the pharmaceutical industry, he now serves as a Wellcome Trust Fellow in the Institute of Psychiatry, Psychology and Neuroscience at King's College London, and has published more than 130 papers.
Dr Eileen Daly, PhD, is a lecturer in the Department of Forensic and Neurodevelopmental Sciences at King's College London, and is the author of more than 120 papers.